Skip to main content

Vertex Pharmaceuticals Inc 10-Q for FY2026 Q3

Vertex Pharmaceuticals Inc (VRTX)

10-Q 2026-11-03 For: 2026-09-30
View Original
Added on November 03, 2026

About this 10-Q

Vertex Pharmaceuticals Inc filed this 10-Q on November 3, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Vertex Pharmaceuticals Inc reported Q3 2026 total revenues of $3.4 billion versus $3.1 billion in Q3 2025. The Crinetics Acquisition added compensation and transaction expenses, while cash, cash equivalents and marketable securities fell to $9.8 billion on September 30, 2026. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$3.44B
up 11.8% from $3.08B a year earlier
Net income
$653.6M
down 39.6% from net income of $1.08B a year earlier
Diluted EPS
$2.56
down 39.0% from $4.20 a year earlier